Association between skeletal muscle mass, visceral fat area, and hyperuricemia in male adolescents - Top-Institutions - MDSpire

Association between skeletal muscle mass, visceral fat area, and hyperuricemia in male adolescents

  • By

  • Wen Mao

  • Qian Li

  • Guangjun Zhu

  • Linyan Cheng

  • Donglian Wang

  • Bo Shen

  • Yufen Zheng

  • January 7, 2026

  • 0 min

Share

Top Institutions in Endocrinology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Endocrinology
    • Metabolism
    • Pediatrics

  • #2

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Endocrinology
    • Pediatric Medicine
    • Metabolic Research

  • #3

    Cincinnati Children's Hospital Medical Center
    Cincinnati Children's Hospital Medical Center

    Cincinnati, OH

    Key Differentiators

    • Pediatric Endocrinology
    • Metabolic Disorders
    • Obesity Research

  • #4

    Harvard Medical School / Massachusetts General Hospital
    Harvard Medical School / Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Endocrinology
    • Metabolic Research
    • Pediatrics

  • #5

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Endocrinology
    • Metabolic Diseases
    • Pediatric Research

Original Source(s)

Association between skeletal muscle mass, visceral fat area, and hyperuricemia in male adolescents

  • by Wen Mao, Qian Li, Guangjun Zhu, Linyan Cheng, Donglian Wang, Bo Shen, Yufen Zheng

  • January 7, 2026

Related Content

GLP-1 Drugs Tied to Lower Addiction Risk

In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.

The role of metabolic reprogramming in oocyte development: research progress and prospects

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.